These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26631102)

  • 1. Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients.
    Kojima T; Takahashi N; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Shioura T; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Terabe K; Takemoto T; Asai N; Ishiguro N
    Clin Rheumatol; 2016 Jan; 35(1):219-25. PubMed ID: 26631102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Fukaya N; Hayashi M; Tsuboi S; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Yoshioka Y; Ishiguro N
    Rheumatology (Oxford); 2015 May; 54(5):854-9. PubMed ID: 25339638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Fukaya N; Ishikawa H; Hayashi M; Tsuboi S; Kanayama Y; Kato D; Funahashi K; Matsubara H; Hattori Y; Hanabayashi M; Hirabara S; Terabe K; Yoshioka Y; Ishiguro N
    Clin Rheumatol; 2014 Jan; 33(1):39-47. PubMed ID: 24057092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Takemoto T; Terabe K; Asai N; Ishiguro N
    J Rheumatol; 2015 May; 42(5):786-93. PubMed ID: 25834204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single-center study.
    Yoshida S; Kotani T; Kimura Y; Matsumura Y; Yoshikawa A; Tokai N; Ozaki T; Nagai K; Takeuchi T; Makino S; Arawaka S
    Int J Rheum Dis; 2019 Jan; 22(1):81-89. PubMed ID: 30168272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.
    Yoshioka Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Kanda H; Takagi H; Ito T; Kato T; Saito K; Funahashi K; Asai S; Takemoto T; Terabe K; Asai N; Ishiguro N; Kojima T
    Mod Rheumatol; 2016; 26(2):169-74. PubMed ID: 26140467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness and safety of additional administration of tacrolimus in rheumatoid arthritis patients with an inadequate response to abatacept: A retrospective cohort study.
    Suzuki M; Takahashi N; Kida D; Hirano Y; Kato T; Yabe Y; Oguchi T; Fujibayashi T; Hayashi M; Asai S; Ishiguro N; Kojima T
    Int J Rheum Dis; 2019 Dec; 22(12):2199-2205. PubMed ID: 31647174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.
    Pomirleanu C; Ancuta C; Miu S; Chirieac R
    Clin Rheumatol; 2013 May; 32(5):665-70. PubMed ID: 23292520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
    Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
    Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
    Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J
    Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients.
    Takahashi N; Kojima T; Terabe K; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Fukaya N; Ishikawa H; Hayashi M; Tsuboi S; Kato D; Funahashi K; Matsubara H; Hattori Y; Hanabayashi M; Hirabara S; Yoshioka Y; Ishiguro N
    Mod Rheumatol; 2013 Sep; 23(5):904-12. PubMed ID: 22975734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) - A prospective, multicenter, single arm pilot clinical trial.
    Yasuda S; Ohmura K; Kanazawa H; Kurita T; Kon Y; Ishii T; Fujieda Y; Jodo S; Tanimura K; Minami M; Izumiyama T; Matsumoto T; Amasaki Y; Suzuki Y; Kasahara H; Yamauchi N; Kato M; Kamishima T; Tsutsumi A; Takemori H; Koike T; Atsumi T
    Mod Rheumatol; 2017 Nov; 27(6):930-937. PubMed ID: 28150514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
    Takahashi N; Fujibayashi T; Kida D; Hirano Y; Kato T; Kato D; Saito K; Kaneko A; Yabe Y; Takagi H; Oguchi T; Miyake H; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Takemoto T; Terabe K; Asai N; Yoshioka Y; Ishiguro N; Kojima T
    Rheumatol Int; 2015 Oct; 35(10):1707-16. PubMed ID: 25991396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Predicting 2 Years of Remission and Low Disease Activity in Rheumatoid Arthritis Patients Treated with TNF-inhibitors.
    Conigliaro P; Triggianese P; Chimenti MS; Tonelli M; Sunzini F; Kroegler B; Perricone R
    Isr Med Assoc J; 2017 Aug; 19(8):467-472. PubMed ID: 28825763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in matrix metalloproteinase-3 independently predicts low disease activity at 52 weeks in bio-switch rheumatoid arthritis patients treated with abatacept.
    Takemoto T; Takahashi N; Kida D; Kaneko A; Hirano Y; Fujibayashi T; Kanayama Y; Hanabayashi M; Yabe Y; Takagi H; Oguchi T; Kato T; Funahashi K; Matsumoto T; Sobue Y; Nishiume T; Suzuki M; Yokota Y; Terabe K; Asai S; Ishiguro N; Kojima T
    Clin Exp Rheumatol; 2020; 38(5):933-939. PubMed ID: 32083543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.
    Mochizuki T; Yano K; Ikari K; Hiroshima R; Takaoka H; Kawakami K; Koenuma N; Shirahata T; Momohara S
    Mod Rheumatol; 2016 Jul; 26(4):499-506. PubMed ID: 26473281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.
    Takeuchi T; Matsubara T; Ohta S; Mukai M; Amano K; Tohma S; Tanaka Y; Yamanaka H; Miyasaka N
    Rheumatology (Oxford); 2015 Apr; 54(4):683-91. PubMed ID: 25257039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.
    Bykerk VP; Burmester GR; Combe BG; Furst DE; Huizinga TWJ; Ahmad HA; Emery P
    Rheumatol Int; 2018 Dec; 38(12):2225-2231. PubMed ID: 30341453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.